Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
Sheikh, SZ; Scheinberg, MA; Wei, JCC; Tegzova, D; Stohl, W; de Toledo, RA; Mucenic, T; Banfi, MRA; Maksimowicz-McKinnon, K; Abud-Mendoza, C; Navarra, S; Garcia, M; Garcia-De La Torre, I; Ros, JO; Levy, RA; Bass, DL; Terres, JR; Punwaney, R; Harris, J; Nami, A; Pierce, A; Thorneloe, KS; Ji, B; Roth, DA
Sheikh, SZ (corresponding author), Univ N Carolina, Rheumatol Allergy & Immunol, Chapel Hill, NC 27599 USA.
LANCET RHEUMATOLOGY, 2021; 3 (2): E122